Quantitative RARβ2 hypermethylation: A promising prostate cancer marker

Carmen Jerónimo, Rui Henrique, Mohammad O. Hoque, Franclim R. Ribeiro, Jorge Oliveira, Daniel Fonseca, Manuel R. Teixeira, Carlos Lopes, David Sidransky

Research output: Contribution to journalArticlepeer-review

Abstract

Retinoic acid receptor β2 (RARβ2) is a tumor suppressor gene frequently hypermethylated in several human neoplasms. To further characterize this epigenetic alteration in prostate cancer progression, we examined tumor tissue from 118 patients with prostate carcinoma (PCa), 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN, and non-neoplastic prostate tissue from 30 patients with benign prostate hyperplasia (BPH), using quantitative methylation-specific PCR. We found RARβ2 hypermethylation in 97.5% of PCa, 94.7% of HGPIN, and 23.3% of BPH. Methylation levels were significantly higher in PCa compared with HGPIN and BPH (P < 0.00001). By establishing an empiric cutoff value, we were able to discriminate between neoplastic and non-neoplastic tissue, with 94.9% sensitivity and 100% specificity. Moreover, RARβ2 methylation levels correlated with higher pathological stage (r = 0.30, P = 0.0009). This quantitative assay represents a novel and promising molecular marker that may augment current approaches for prostate cancer detection.

Original languageEnglish (US)
Pages (from-to)4010-4014
Number of pages5
JournalClinical Cancer Research
Volume10
Issue number12 I
DOIs
StatePublished - Jul 15 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Quantitative RARβ2 hypermethylation: A promising prostate cancer marker'. Together they form a unique fingerprint.

Cite this